LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.14 -0.87

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.12

Max

1.1400000000000001

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.5M -20M
EPS	-0.32
Angestellte	49
EBITDA	6.6M -22M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+132.17% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6.8M 74M
Vorheriger Eröffnungskurs	2.01
Vorheriger Schlusskurs	1.14

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Mai 2026, 23:53 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15. Mai 2026, 22:47 UTC

Heiße Aktien

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. Mai 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. Mai 2026, 22:00 UTC

Wichtige Markttreiber

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. Mai 2026, 18:09 UTC

Wichtige Markttreiber

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17. Mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17. Mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17. Mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17. Mai 2026, 23:07 UTC

Akquisitionen, Fusionen, Übernahmen

UOB: Transactions Part of Group's Capital Reallocation Strategy

17. Mai 2026, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

UOB: Share Sale Agreements Entered With Singland Properties

17. Mai 2026, 23:05 UTC

Akquisitionen, Fusionen, Übernahmen

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17. Mai 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Fund Stake Acquisition via Internal Resources

17. Mai 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Acquire Stake for $389 Million

17. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16. Mai 2026, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16. Mai 2026, 15:26 UTC

Akquisitionen, Fusionen, Übernahmen

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16. Mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. Mai 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. Mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 20:19 UTC

Heiße Aktien

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. Mai 2026, 19:41 UTC

Akquisitionen, Fusionen, Übernahmen

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. Mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. Mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. Mai 2026, 18:35 UTC

Ergebnisse

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

132.17% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 132.17%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.